StreetAlpha.app
Home › Stocks › PROK

Prokidney Corp. (PROK)

Healthcare
$1.10
▲ +5.77%
LAST CLOSE · NOV 17

ProKidney develops rilparencel, a cell therapy aimed at preserving kidney function in people with chronic kidney disease and diabetes. It last closed at $1.10 on Nov 17, up 5.77% on the day.

AI Auto Pilots
Is PROK in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$775K
+4.2% vs a year ago
Net income
−$103.3M
−13326.7% margin
Free cash flow
−$167.8M
−21655.0% margin
Operating margin
−24830.3%
−$192.4M operating income
Balance sheet
Cash & equivalents
$81.4M
At Sep 30
Shareholder equity
−$906.9M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $76K$76KFY2024FY2025: $893K$893KFY2025

From PROK's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated PROK in the past 90 days, not enough for a consensus
Average 12-month target
$8.00
▲ 627.3% upside

Based on 1 analyst who set a price target on PROK in the past 90 days. The average target is $8.00, with a high of $8.00 and a low of $8.00, compared with the last close of $1.10.

Low $8.00Avg $8.00High $8.00
Blue marker: last close $1.10
Highest target$8.00
Average target$8.00
Lowest target$8.00
Latest rating changes
CitigroupMaintained
Oct 28Buy$8
HC Wainwright & Co.Reiterated
May 18Buy$12
DateFirmActionRatingPrice target
Oct 28CitigroupMaintainedBuy$8
May 18HC Wainwright & Co.ReiteratedBuy$12
Loading…

Technical Analysis

PROK · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 12% below its 20 day and 36% below its 50 day average. It is 60% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38), near oversold. The nearest support is the Pivot at $1.09, and the nearest resistance the Pivot R1 at $1.14.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 11.3%/day
Key levels
$2.6552 week high+140.9%
$1.76200 day average+60.0%
$1.59100 day average+44.5%
$1.4950 day average+35.5%
$1.27Swing high (Nov 9)+15.5%
$1.2420 day average+12.7%
$1.14Pivot R1+3.6%
$1.10Last close
$1.09Pivot−0.9%
$1.05Pivot S1−4.5%
$0.8752 week low−20.9%
$0.87Swing low (Nov 2)−20.9%
Indicators
RSI (14)37.66Weak, oversold below 30Neutral
MACD-0.12Below its signal lineBearish
Stochastic27.4Middle of its rangeNeutral
ADX (14)28.0Trending down
Williams %R-65.2Oversold below −80, overbought above −20Neutral
CCI (20)-62.4Oversold below −100, overbought above 100Neutral
Rate of change+2.8%Change over 10 sessionsBullish
ATR (14)$0.12Typical daily range, 11.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PROK

What happened before

See how PROK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PROK usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PROK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PROK in the last 90 days.

Loading…

See today’s whale options flow across the market →

PROK Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲56 buying vs 27 selling
  • ▲Shares held by funds +13.7%
  • ▲Funds holding +20
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding9171+28.2%
In funds' top 1001−100.0%
Held by funds–––
New / increased26 / 3022 / 25+19.1%
Reduced / sold out20 / 711 / 21−15.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PROK institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PROK is in one of them and how their past PROK trades turned out.

PROK in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PROK in an article yet. Here's the latest on the wider market.

About Prokidney

ProKidney is a biotechnology company developing rilparencel, a cell therapy meant to preserve kidney function in patients with chronic kidney disease and type 2 diabetes. The treatment is made from a patient's own kidney cells, which are collected from a small kidney biopsy, processed at the company's facility, and then injected back into the kidneys. The company is based in Winston-Salem, North Carolina, and its product is still in clinical development.

Headquarters
Winston-Salem, NC